Bio-Rad Laboratories Net Profit Margin 2006-2018 | BIO
Current and historical net profit margin for Bio-Rad Laboratories (BIO) from 2006 to 2018. Net profit margin can be defined as net Income as a portion of total sales revenue. Bio-Rad Laboratories net profit margin for the three months ending December 31, 2018 was .
| Bio-Rad Laboratories Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2018-12-31 | $2.29B | $0.37B | 15.94% |
| 2018-09-30 | $2.29B | $1.28B | 55.67% |
| 2018-06-30 | $2.28B | $1.03B | 45.12% |
| 2018-03-31 | $2.21B | $0.77B | 34.67% |
| 2017-12-31 | $2.16B | $0.12B | 5.65% |
| 2017-09-30 | $2.11B | $0.02B | 0.76% |
| 2017-06-30 | $2.09B | $0.01B | 0.58% |
| 2017-03-31 | $2.10B | $0.03B | 1.19% |
| 2016-12-31 | $2.07B | $0.03B | 1.21% |
| 2016-09-30 | $2.07B | $0.09B | 4.55% |
| 2016-06-30 | $2.03B | $0.09B | 4.58% |
| 2016-03-31 | $2.02B | $0.10B | 5.10% |
| 2015-12-31 | $2.02B | $0.11B | 5.40% |
| 2015-09-30 | $2.05B | $0.10B | 4.98% |
| 2015-06-30 | $2.11B | $0.10B | 4.60% |
| 2015-03-31 | $2.14B | $0.10B | 4.72% |
| 2014-12-31 | $2.18B | $0.09B | 4.14% |
| 2014-09-30 | $2.18B | $0.08B | 3.72% |
| 2014-06-30 | $2.15B | $0.06B | 2.88% |
| 2014-03-31 | $2.14B | $0.07B | 3.03% |
| 2013-12-31 | $2.13B | $0.08B | 3.66% |
| 2013-09-30 | $2.10B | $0.09B | 4.33% |
| 2013-06-30 | $2.10B | $0.14B | 6.72% |
| 2013-03-31 | $2.08B | $0.15B | 7.39% |
| 2012-12-31 | $2.07B | $0.17B | 7.97% |
| 2012-09-30 | $2.05B | $0.18B | 8.90% |
| 2012-06-30 | $2.06B | $0.19B | 8.97% |
| 2012-03-31 | $2.08B | $0.18B | 8.53% |
| 2011-12-31 | $2.07B | $0.18B | 8.63% |
| 2011-09-30 | $2.06B | $0.19B | 9.09% |
| 2011-06-30 | $2.01B | $0.19B | 9.24% |
| 2011-03-31 | $1.96B | $0.18B | 9.39% |
| 2010-12-31 | $1.93B | $0.19B | 9.65% |
| 2010-09-30 | $1.89B | $0.16B | 8.26% |
| 2010-06-30 | $1.88B | $0.15B | 7.99% |
| 2010-03-31 | $1.84B | $0.15B | 8.17% |
| 2009-12-31 | $1.78B | $0.15B | 8.13% |
| 2009-09-30 | $1.74B | $0.10B | 5.70% |
| 2009-06-30 | $1.72B | $0.09B | 5.12% |
| 2009-03-31 | $1.74B | $0.09B | 5.34% |
| 2008-12-31 | $1.76B | $0.09B | 5.05% |
| 2008-09-30 | $1.78B | $0.11B | 6.14% |
| 2008-06-30 | $1.67B | $0.11B | 6.51% |
| 2008-03-31 | $1.56B | $0.09B | 5.89% |
| 2007-12-31 | $1.46B | $0.09B | 6.36% |
| 2007-09-30 | $1.35B | $0.10B | 7.29% |
| 2007-06-30 | $1.31B | $0.09B | 7.10% |
| 2007-03-31 | $1.29B | $0.10B | 7.68% |
| 2006-12-31 | $1.27B | $0.10B | 8.08% |
| 2006-09-30 | $1.24B | $0.10B | 8.00% |
| 2006-06-30 | $1.22B | $0.09B | 7.57% |
| 2006-03-31 | $1.19B | $0.08B | 6.56% |
| 2005-12-31 | $1.18B | $0.08B | 6.78% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $8.765B | $2.290B |
| Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company's products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $129.838B | 25.32 |
| Medtronic (MDT) | Ireland | $112.952B | 16.51 |
| Stryker (SYK) | United States | $67.256B | 24.66 |
| Boston Scientific (BSX) | United States | $48.820B | 23.72 |
| Baxter (BAX) | United States | $37.991B | 24.37 |
| Zimmer Biomet Holdings (ZBH) | United States | $24.550B | 15.71 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.615B | 0.00 |
| Canopy Growth (CGC) | Canada | $14.912B | 0.00 |
| ResMed (RMD) | United States | $14.218B | 26.96 |
| Aurora Cannabis (ACB) | Canada | $9.118B | 64.29 |
| Perrigo (PRGO) | Ireland | $6.633B | 10.75 |
| Hill-Rom Holdings (HRC) | United States | $6.374B | 19.72 |
| Insulet (PODD) | United States | $4.900B | 1642.60 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.701B | 0.00 |
| ICU Medical (ICUI) | United States | $4.568B | 28.29 |
| Haemonetics (HAE) | United States | $4.189B | 37.16 |
| Hutchison China MediTech (HCM) | China | $4.046B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.268B | 0.00 |
| Neogen (NEOG) | United States | $2.958B | 48.10 |
| NuVasive (NUVA) | United States | $2.784B | 24.18 |
| Quidel (QDEL) | United States | $2.365B | 21.17 |
| National Vision Holdings (EYE) | United States | $2.220B | 43.66 |
| Aphria (APHA) | $1.917B | 0.00 | |
| Phibro Animal Health (PAHC) | United States | $1.349B | 19.38 |
| VAREX IMAGING (VREX) | United States | $1.222B | 23.93 |
| Cardiovascular Systems (CSII) | United States | $1.190B | 854.00 |
| AtriCure (ATRC) | United States | $1.049B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.931B | 25.16 |
| Omeros (OMER) | United States | $0.908B | 0.00 |
| PetIQ (PETQ) | United States | $0.862B | 24.67 |
| MacroGenics (MGNX) | United States | $0.791B | 0.00 |
| Cerus (CERS) | United States | $0.787B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.737B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.689B | 0.00 |
| Evolus (EOLS) | United States | $0.681B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.666B | 22.66 |
| OraSure Technologies (OSUR) | United States | $0.594B | 25.86 |
| Surmodics (SRDX) | United States | $0.546B | 79.43 |
| LeMaitre Vascular (LMAT) | United States | $0.536B | 25.46 |
| Meridian Bioscience (VIVO) | United States | $0.531B | 15.82 |
| Quanterix (QTRX) | United States | $0.492B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.322B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.321B | 20.88 |
| Insys Therapeutics (INSY) | United States | $0.313B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.305B | 125.85 |
| Vapotherm (VAPO) | United States | $0.296B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.271B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.219B | 0.00 |
| Owens & Minor (OMI) | United States | $0.213B | 2.91 |
| Zynex (ZYXI) | United States | $0.171B | 18.31 |
| Chimerix (CMRX) | United States | $0.133B | 0.00 |
| Bovie Medical (APYX) | United States | $0.131B | 0.00 |
| Fonar (FONR) | United States | $0.125B | 6.68 |
| Chembio Diagnostics (CEMI) | United States | $0.121B | 0.00 |
| Surface Oncology (SURF) | United States | $0.113B | 0.00 |
| Female Health (VERU) | United States | $0.088B | 0.00 |
| United-Guardian (UG) | United States | $0.088B | 20.06 |
| CAS Medical Systems (CASM) | United States | $0.072B | 0.00 |
| Neurotrope (NTRP) | United States | $0.071B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.071B | 21.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.070B | 0.00 |
| ImmuCell (ICCC) | United States | $0.043B | 0.00 |
| Senestech (SNES) | United States | $0.034B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.031B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.025B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.018B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 13.71 |
